XENE vs ZBIO Stock Comparison

XENE currently leads ZBIO in this stock comparison, with AIQ scores of 49 vs 47. The clearest difference is quality, while ZBIO has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 2 points
XENE
Healthcare
vs
ZBIO
Healthcare
XENE
Xenon Pharmaceuticals Inc.
Leads
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Quality
Sector
Healthcare
ZBIO
Zenas BioPharma, Inc.
Price
$28.01
Day move
+1.34%
AIQ Score
47/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between XENE and ZBIO?

XENE leads the current stock comparison as Xenon Pharmaceuticals Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Xenon Pharmaceuticals Inc. vs Zenas BioPharma, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

XENE leads

XENE leads by 2 AIQ points, primarily on Quality and Risk Resilience. Wall Street currently favors ZBIO on target upside.

Fragile: 2 of 5 evidence groups support XENE.

Evidence agreement: 2 of 5Comparison trend: Stable
XENE

Xenon Pharmaceuticals Inc.

Leads
AIQ Score
49/100
AIQ Edge Score
8/10
ZBIO

Zenas BioPharma, Inc.

AIQ Score
47/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors XENE over ZBIO, 49 versus 47 as of Nov 15, 2026. XENE's advantage is driven primarily by stronger quality and risk resilience, while ZBIO holds the stronger momentum profile. XENE also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ZBIO. 2 of 5 covered evidence groups favor XENE today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. XENE lead: Stable — the AIQ differential has held near 2 points over 30 sessions.

Compare Xenon Pharmaceuticals Inc. and Zenas BioPharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

XENE
-0.9%
ZBIO
+54.3%

Price return comparison

Growth of $10,000, price only

XENE $9,912 · ZBIO $15,433

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare XENE and ZBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

XENE advantage
0
ZBIO advantage
  • Momentum33 vs 78
    ZBIO +45
  • Quality68 vs 25
    XENE +43
  • Risk Resilience49 vs 39
    XENE +10

2 of 5 evidence groups favor XENE. XENE’s edge is concentrated in quality and risk resilience; ZBIO keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)
ZBIO+1 AIQ

Largest factor move: Momentum +2

New signals

  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
  • RSI Midline Reclaim — bullish, momentum, short horizon

XENE's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — XENE and ZBIO both carry a full feed there.

The central trade-off

XENE (Xenon Pharmaceuticals Inc.): the stronger current systematic profile, led by quality and risk resilience.

ZBIO (Zenas BioPharma, Inc.): the counter-case, on momentum, technicals, analyst expectations — but at materially higher volatility, 65.7% against 38%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

XENE

XENE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ZBIO

ZBIO on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

ZBIO

ZBIO on the Momentum factor, by 45 points.

Lower downside

XENE

XENE on Risk Resilience, by 10 points.

Analyst upside

ZBIO

ZBIO on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors XENE, analyst targets favor ZBIO. That disagreement is the most useful thing on this page.

MeasureXENEZBIONote
Implied upside to target+67.6%+96.4%ZBIO has more room
Target dispersion+64.8%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering188Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor XENE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven49 vs 47
FundamentalsXENETTM ROE -9.6% vs -51.3%
ValuationNot coveredNot covered
TechnicalsZBIOPrice vs 50-day -1.6% vs -2%; vs 200-day -22.6% vs 10.5%
Risk ResilienceXENERisk Resilience 49 vs 39
Analyst expectationsZBIOTarget upside 67.6% vs 96.4%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of XENE and ZBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XENE.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

XENE lead: Stable — the AIQ differential has held near 2 points over 30 sessions.

May 27XENE leads above the line · ZBIO leads belowNov 13
Today
XENE +2
49 vs 47
7 sessions ago
XENE +3
49 vs 46
30 sessions ago
XENE +3
46 vs 43
90 sessions ago
XENE +28
73 vs 45

The lead changed hands once in this window, most recently on Sep 28 when ZBIO moved ahead of XENE.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • Death Cross Active — bearish, trend, long horizon (27.10%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Downtrend Structure Active — bearish, trend, long horizon
ZBIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only ZBIO

  • Golden Cross Active — bullish, trend, long horizon (12.78%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • RSI Midline Reclaim — bullish, momentum, short horizon

Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, Low Volume Rally Warning.

ZBIO is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

ZBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.34%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ZBIO closes the Quality gap — currently 43 points behind, the largest single contributor to XENE's edge.
  2. 2ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3XENE starts generating bearish momentum or trend signals.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

XENE leads on balance
MetricXENEZBIO
Revenue growth (YoY)0%9%
EPS growth (YoY)0%6.8%
Gross margin0%-6.6%
Operating margin0%-47.9%
Return on equity (TTM)-9.6%-51.3%
Debt to equity0.011.42

Performance

XENE leads 4 of 6 windows
MetricXENEZBIO
1 week (5 sessions)3.3%-0.9%
1 month (20 sessions)20.9%12.8%
3 months (63 sessions)-35.1%-8.2%
6 months (126 sessions)-25.6%52.7%
Year to date-9.7%-22.9%
1 year (252 sessions)2%-21.8%

Technicals

ZBIO has the stronger structure
MetricXENEZBIO
RSI (14)54.950.1
ADX (14)2412.2
Price vs 50-day-1.6%-2%
Price vs 200-day-22.6%10.5%
Volatility (1M, annualized)38%65.7%

Risk

XENE is the more resilient
MetricXENEZBIO
Beta0.860.75
Sharpe ratio0.270.26
Sortino ratio0.480.34
Max drawdown-52.8%-64.8%
Current drawdown-43%-35.1%
Annualized volatility68.1%95.3%
Value at risk (95%)-3.3%-7.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, XENE or ZBIO?

On the Algovestiq AIQ Score, XENE is the stronger of the two as of Nov 15, 2026, scoring 49 against ZBIO's 47. The edge comes from quality and risk resilience. ZBIO is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is XENE or ZBIO the better buy right now?

XENE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.

Why does the AIQ Score favor XENE over ZBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. ZBIO leads Momentum by 45 points; XENE leads Quality by 43 points; XENE leads Risk Resilience by 10 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, XENE or ZBIO?

Analyst price targets imply +67.6% upside for XENE and +96.4% for ZBIO, so the Street currently favors ZBIO. That points the opposite way to the AIQ Score, which favors XENE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, XENE or ZBIO?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, XENE or ZBIO?

ZBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, XENE or ZBIO?

ZBIO on the Momentum factor, by 45 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, XENE or ZBIO?

XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE on Risk Resilience, by 10 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is XENE more profitable than ZBIO?

XENE leads on the comparable margin measures — gross margin 0% vs -6.6%; operating margin 0% vs -47.9%; ttm roe -9.6% vs -51.3%.

Is XENE's lead over ZBIO getting stronger or weaker?

XENE lead: Stable — the AIQ differential has held near 2 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-09-28, when ZBIO moved ahead of XENE.

What would change the XENE vs ZBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZBIO closes the Quality gap — currently 43 points behind, the largest single contributor to XENE's edge; ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; XENE starts generating bearish momentum or trend signals; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about XENE and ZBIO?

XENE: 0 bullish / 3 bearish / 2 neutral. ZBIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on XENE is Death Cross Active (bearish, long horizon). On ZBIO it is Golden Cross Active (bullish, long horizon).

Compare XENE and ZBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.